C
ClearPoint Neuro, Inc.
CLPTCIK 0001285550NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31
Period
FY 2025
Revenue
$36.97M
Net Income
$-25.54M
Total Assets
$97.75M
Equity
$28.02M
Shares Out
29.66M
Op. Cash Flow
$-23.90M
Business
ClearPoint Neuro, Inc. develops and commercializes platforms for minimally invasive neurosurgical procedures guided by MRI and for operating room use. Its main products and services include the ClearPoint navigation system with hardware, disposables (SmartFrame, SmartFlow) and software, the ClearPoint Prism Neuro Laser Therapy System, and consulting and preclinical drug delivery services. The company operates through two components: medical devices for neurosurgical applications and partnerships offering biologics and drug-delivery development services. It markets directly to neurosurgeons, hospitals and pharmaceutical/biotech partners and distributes systems and disposables to clinical centers globally.
Summary from filing dated 2025-02-26
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 37 | 31 | 24 | 21 | 16 | |
| Cost of revenue | 14 | 12 | 10 | 7 | 5 | |
| Gross profit | 23 | 19 | 14 | 14 | 11 | |
| Research and development costs | 14 | 12 | 12 | 11 | 9 | |
| Sales and marketing expenses | 16 | 14 | 13 | 9 | 7 | |
| General and administrative expenses | 16 | 12 | 12 | 10 | 8 | |
| Operating loss | −24 | −20 | −22 | −16 | −13 | |
| Other expense, net | −146,000 | −40,000 | −29,000 | −22,000 | −63,000 | |
| Interest income | 1 | 1 | — | — | — | |
| Interest expense | −2 | −518,000 | — | — | — | |
| Net loss before income taxes | −25 | −19 | — | — | — | |
| Income tax expense | 55,000 | 12,000 | — | — | — | |
| Net loss | −26 | −19 | −22 | −16 | −14 | |
| Basic (in dollars per share) | −0.9 | −0.7 | −0.9 | −0.68 | −0.69 | |
| Diluted (in dollars per share) | −0.9 | −0.7 | −0.9 | −0.68 | −0.69 | |
| Basic (in shares) | 28 | 27 | 25 | 24 | 21 | |
| Diluted (in shares) | 28 | 27 | 25 | 24 | 21 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 46 | 20 | 23 | 28 | 54 | |
| Accounts receivable, net | 7 | 5 | 3 | 3 | 2 | |
| Inventory, net | 8 | 7 | 8 | 9 | 5 | |
| Prepaid expenses and other current assets | 3 | 2 | 2 | 2 | 508,000 | |
| Total current assets | 64 | 33 | 36 | 51 | 62 | |
| Property and equipment, net | 3 | 2 | 1 | 806,000 | 539,000 | |
| Operating lease, right-of-use assets | 8 | 3 | 4 | 2 | 2 | |
| Goodwill | 7 | 0 | — | — | — | |
| Intangible assets, net | 14 | 0 | — | — | — | |
| Other assets | 2 | 735,000 | 109,000 | 131,000 | 125,000 | |
| Total assets | 98 | 39 | 43 | 55 | 66 | |
| Accounts payable | 1 | 1 | 393,000 | 272,000 | 427,000 | |
| Accrued compensation | 4 | 5 | 3 | 3 | 3 | |
| Other accrued liabilities | 3 | 1 | 1 | 2 | 537,000 | |
| Operating lease liabilities, current portion | 694,000 | 557,000 | 424,000 | 561,000 | 507,000 | |
| Contract liabilities, current portion | 2 | 2 | — | — | — | |
| Total current liabilities | 11 | 10 | 7 | 7 | 5 | |
| Operating lease liabilities, net of current portion | 8 | 3 | 4 | 2 | 2 | |
| Contract liabilities, net of current portion | 581,000 | 436,000 | — | — | — | |
| Long-term notes payable, net | 49 | 0 | — | — | — | |
| Deferred tax liabilities, net | 354,000 | 0 | — | — | — | |
| Other long-term liabilities | 489,000 | 0 | — | — | — | |
| Total liabilities | 70 | 14 | 21 | 19 | 17 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Preferred stock, $0.01 par value; 25,000,000 shares authorized at December 31, 2025 and 2024; none issued and outstanding at December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.01 par value; 90,000,000 shares authorized at December 31, 2025 and 2024; 29,368,760 and 27,617,415 shares issued and outstanding at December 31, 2025 and 2024, respectively | 294,000 | 276,000 | 247,000 | 246,000 | 237,000 | |
| Additional paid-in capital | 239 | 216 | 193 | 187 | 182 | |
| Shares to be issued | 6 | 0 | — | — | — | |
| Accumulated deficit | −217 | −191 | −172 | −150 | −134 | |
| Total stockholders equity | 28 | 25 | 21 | 37 | 49 | |
| Total liabilities and stockholders equity | 98 | 39 | 43 | 55 | 66 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Allowance for credit losses (recoveries) | 21,000 | −296,000 | 1 | −117,000 | 202,000 | |
| Depreciation and amortization | 814,000 | 980,000 | 626,000 | 244,000 | 159,000 | |
| Amortization of intangible assets | 168,000 | 0 | — | — | — | |
| Share-based compensation | 8 | 7 | 6 | 4 | 2 | |
| Payment-in-kind interest | 908,000 | 0 | — | 0 | 325,000 | |
| Amortization of debt issuance costs and original issue discounts | 83,000 | 51,000 | 57,000 | 55,000 | 100,000 | |
| Amortization of lease right of use assets, net of accretion in lease liabilities | 1 | 923,000 | 831,000 | 533,000 | 533,000 | |
| Accounts receivable | −268,000 | −1 | −2 | −211,000 | −658,000 | |
| Inventory, net | −103,000 | 743,000 | 1 | −4 | −2 | |
| Prepaid expenses and other current assets | −397,000 | 262,000 | −113,000 | −1 | −264,000 | |
| Other assets | −195,000 | −39,000 | 22,000 | −6,000 | −66,000 | |
| Accounts payable and accrued expenses | −8 | 3 | −649,000 | 2 | 1 | |
| Lease liabilities | −1 | −869,000 | −755,000 | −541,000 | — | |
| Contract liabilities | −319,000 | −597,000 | — | — | — | |
| Net cash flows from operating activities | −24 | −9 | −14 | −16 | −13 | |
| Cash acquired in business combination, net of cash paid | 1 | 0 | — | — | — | |
| Purchases of property and equipment | −522,000 | −275,000 | −717,000 | −253,000 | −168,000 | |
| Net cash flows from investing activities | 615,000 | −275,000 | 9 | −11 | −168,000 | |
| Proceeds from offerings of common stock, net of offering costs | 3 | 16 | 0 | 0 | 47 | |
| Proceeds from issuance of notes payable, net of financing costs and discount | 48 | 0 | — | — | — | |
| Repayment of 2020 senior secured convertible note | 0 | −10 | 0 | — | — | |
| Proceeds from stock option exercises | 127,000 | 21,000 | 0 | — | — | |
| Payments for taxes related to net share settlement of equity awards | −2 | −424,000 | −210,000 | −336,000 | −599,000 | |
| Proceeds from issuance of common stock under employee stock purchase plan | 559,000 | 443,000 | 506,000 | 477,000 | 224,000 | |
| Net cash flows from financing activities | 50 | 6 | 296,000 | 409,000 | 47 | |
| Net change in cash, cash equivalents and restricted cash | 27 | −3 | −4 | −26 | 34 | |
| Income taxes | 69,000 | 62,000 | 0 | 0 | 0 | |
| Interest | 908,000 | 480,000 | 743,000 | 523,000 | 597,000 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro